search returned 100 results for adalimumab, showing results 61 to 70
to the board to reconsider the prescribing of
methotrexate by NP’s.
12.2 Adalimumab for uveitis...) and they are looking to make a submission to the
PBAC to get adalimumab on the PBS for uveitis
• Most patients with uveitis needing biologic treatment access adalimumab
through the AbbVie
https://rheumatology.org.au/LinkClick.aspx?fileticket=_xZA7E0in-E%3d&portalid=2
Considerations
Tocilizumab IV
80mg/4mL
RA Yes Yes Multiple
Polyarticular JIA Yes Yes Adalimumab... Yes Multiple
Polyarticular JIA Yes Yes Adalimumab
Etanercept
Systemic JIA Yes No Anakinra... Adalimumab
Etanercept
Systemic JIA Yes No Anakinra
Canakinumab
Alternatives not available
https://rheumatology.org.au/LinkClick.aspx?fileticket=aWDwEOcgN9k%3d
2025 - Ltr to PBAC re proposed changes to PBS listings for adalimumab for certain paediatric... 2024 - Ltr to PBAC re adalimumab for juvenile AS
28 June 2024 - Ltr to PBAC re adalimumab for JIA
6 May 2024 - Response from PBAC re: listing of adalimumab for immune-mediated inflammatory
https://rheumatology.org.au/For-Members/My-Portal/ARA-Advocacy/External-Correspondence
of the current
PBS listing is sought
Note
Adalimumab Non-infectious
inflammatory uveitis
(including... on adalimumab for non-infectious intermediate, posterior or panuveitis done by Government
agencies... analysis has therefore shifted considerably. Adalimumab is a highly effective, evidence-
based
https://rheumatology.org.au/LinkClick.aspx?fileticket=SxKNQJaq5Ew%3d
of the current
PBS listing is sought
Note
Adalimumab Non-infectious
inflammatory uveitis
(including... on adalimumab for non-infectious intermediate, posterior or panuveitis done by Government
agencies... analysis has therefore shifted considerably. Adalimumab is a highly effective, evidence-
based
https://rheumatology.org.au/LinkClick.aspx?fileticket=SxKNQJaq5Ew%3d&portalid=2
review (see
agenda item 11)
• WR advised that he has drafted an evidence-based letter on adalimumab...
Agenda Item
13 March PBAC 2024 Meeting Agenda items to submit comments
• Adalimumab for vision... as biologic.
ACTIONS:
• As discussed above.
• WR to draft adalimumab for vision threatening
https://rheumatology.org.au/LinkClick.aspx?fileticket=BwHiBtwd0MM%3d
review (see
agenda item 11)
• WR advised that he has drafted an evidence-based letter on adalimumab...
Agenda Item
13 March PBAC 2024 Meeting Agenda items to submit comments
• Adalimumab for vision... as biologic.
ACTIONS:
• As discussed above.
• WR to draft adalimumab for vision threatening
https://rheumatology.org.au/LinkClick.aspx?fileticket=BwHiBtwd0MM%3d&portalid=2
as of 1 July
o Adalimumab is now PBS-listed for vision threatening non-infectious uveitis as of
1 Aug.
• Additionally, AbbVie has submitted a broad proposal for adalimumab in immune-
mediated... adalimumab for juvenile AS
o adalimumab for JIA.
TC Minutes 19 August 24 – Final Page 4
https://rheumatology.org.au/LinkClick.aspx?fileticket=HMRXYKz9vFs%3d
Zealand
and had been stable on adalimumab for ankylosing spondylitis. Despite documentation
https://rheumatology.org.au/LinkClick.aspx?fileticket=3fOeL6on48Q%3d
) is now listed on the PBS as an unrestricted benefit.
• Adalimumab is now TGA listed for the treatment
https://rheumatology.org.au/LinkClick.aspx?fileticket=7e5qwzowkok%3d